Effect of Rising Chemotherapy Costs on the Cost Savings of Colorectal Cancer Screening

Lansdorp–Vogelaar, Iris; Ballegooijen, Marjolein van; Zauber, Ann G.; Habbema, J. Dik F.; Kuipers, Ernst J.

doi:10.1093/jnci/djp319

Cited by 167 publications

(143 citation statements)

References 52 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…This leads to an overall increase in the total medical cost for all screening strategies as compared to no-screening. Previous cost-effectiveness analyses 40,41 do not take other medical costs into account and likely underestimate the economic costs of CRC screening. These increased costs still fall within conventional criteria for cost-effectiveness, but represent a more realistic assessment of actual costs associated with a CRC screening program.…”

Section: Discussionmentioning

confidence: 99%

“…Costs of CRC screening and surveillance in the general US population are also consistent with previous cost-effectiveness studies. 40 Patients who have been diagnosed with diabetes at age 50 gained fewer life years from CRC screening than those without diabetes at age 50. On average, for the same screening strategy, a person without diabetes at age 50 will gain 0.07-0.13 life years more than a person with diabetes at baseline ( Table 2).…”

Section: Role Of the Funding Sourcementioning

confidence: 99%

See 1 more Smart Citation

Impact of Comorbidity on Colorectal Cancer Screening Cost-Effectiveness Study in Diabetic Populations

Dinh¹,

Alperin²,

Walter

et al. 2012

J GEN INTERN MED

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Role Of the Funding Sourcementioning

confidence: 99%

Impact of Comorbidity on Colorectal Cancer Screening Cost-Effectiveness Study in Diabetic Populations

Dinh¹,

Alperin²,

Walter

et al. 2012

J GEN INTERN MED

View full text Add to dashboard Cite

“…Of the above described tests, only the fecal occult blood tests meet the WHO criteria for screening. As published recently, most CRC screening strategies lead not only to a reduction in CRC incidence and mortality, but also to better control of the costs of CRC treatment, especially with increased chemotherapy costs for advanced CRC [26] .…”

Section: Screening Methodsmentioning

confidence: 99%

Colorectal cancer screening in Europe

Zavoral¹,

Suchánek²,

Závada³

et al. 2009

WJG

168

114

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second most frequent malignant disease in Europe. Every year, 412 000 people are diagnosed with this condition, and 207 000 patients die of it. In 2003, recommendations for screening programs were issued by the Council of the European Union (EU), and these currently serve as the basis for the preparation of European guidelines for CRC screening. The manner in which CRC screening is carried out varies significantly from country to country within the EU, both in terms of organization and the screening test chosen. A screening program of one sort or another has been implemented in 19 of 27 EU countries. The most frequently applied method is testing stool for occult bleeding (fecal occult blood test, FOBT). In recent years, a screening colonoscopy has been introduced, either as the only method (Poland) or the method of choice (Germany, Czech Republic).

show abstract

“…Chemotherapy costs have gone up throughout the years and thus screening and preventing advanced CRC can prevent costs associated with cancer diagnosis. One study found that when compared with no screening, the savings from treatment by preventing CRC and deaths secondary to CRC doubled with the use of new chemotherapy agents [4,85].…”

Section: Discussionmentioning

confidence: 99%